The Quality of Life Among Men Receiving Active Surveillance for Prostate Cancer: An Integrative Review

Overview

Journal Healthcare (Basel)

Specialty Health Services

Date 2019 Jan 26

PMID 30678213

Citations 5

Authors

Sabrina L Dickey

Ciara J Grayson

Affiliations

Soon will be listed here.

Abstract

Prostate cancer is very common among men in the United States. The current literature on active surveillance (AS) suggests that it is a promising treatment option for men with low-risk prostate cancer. The purpose of this manuscript is to provide a thorough integrative review regarding the effects of AS on the quality of life (QoL) of men with prostate cancer. Utilizing a methodological strategy, electronic databases were reviewed for empirical articles during the time frame of January 2006 to December 2016. A total of 37 articles met the inclusion criteria wherein 20 focused on the QoL among men only receiving AS and 16 reported QoL among men undergoing AS and other forms of treatment for prostate cancer. The review highlights the purpose, common instruments, race and ethnicity, and strengths and limitations of each article. The majority of articles indicated low levels of anxiety and depression and decreased incidences of bladder, bowel and sexual functioning among men undergoing AS in comparison to men who received other treatment modalities. The results indicated that additional research is needed to determine the QoL among men receiving AS on a longitudinal basis. The results support previous literature that indicated the positive impact of AS on low-risk prostate cancer.

Citing Articles

Patients' representation of oncological disease: psychological aspects in the cancer journey.

Durosini I, Pravettoni G Front Psychol. 2023; 14:1087083.

PMID: 37502747 PMC: 10371254. DOI: 10.3389/fpsyg.2023.1087083.

Applications of Focused Ultrasound in the Treatment of Genitourinary Cancers.

Panzone J, Byler T, Bratslavsky G, Goldberg H Cancers (Basel). 2022; 14(6).

PMID: 35326687 PMC: 8945954. DOI: 10.3390/cancers14061536.

Cognitive and Psychological Impacts of Different Treatment Options for Prostate Cancer: A Critical Analysis.

Yiannopoulou K, Anastasiou A, Kontoangelos K, Papageorgiou C, Anastasiou I Curr Urol. 2021; 14(4):169-177.

PMID: 33488334 PMC: 7810213. DOI: 10.1159/000499242.

Dynamic Changes of Generic Quality of Life after Different Treatments for Localized Prostate Cancer.

Kao Y, Ou C, Lin S, Chang S, Wang J, Tsai Y J Clin Med. 2021; 10(1).

PMID: 33466363 PMC: 7795146. DOI: 10.3390/jcm10010158.

Abdominal aortic aneurysm in prostate cancer patients: the "road map" from incidental detection to advanced predictive, preventive, and personalized approach utilizing common follow-up for both pathologies.

Ferda J, Baxa J, Ferdova E, Kucera R, Topolcan O, Molacek J EPMA J. 2019; 10(4):415-423.

PMID: 31832115 PMC: 6882970. DOI: 10.1007/s13167-019-00193-y.

References

Seiler D, Randazzo M, Leupold U, Zeh N, Isbarn H, Chun F . Protocol-based active surveillance for low-risk prostate cancer: anxiety levels in both men and their partners. Urology. 2012; 80(3):564-9. DOI: 10.1016/j.urology.2012.04.053. View

Cooperberg M, Carroll P, Klotz L . Active surveillance for prostate cancer: progress and promise. J Clin Oncol. 2011; 29(27):3669-76. DOI: 10.1200/JCO.2011.34.9738. View

Ganz P, Barry J, Burke W, Col N, Corso P, Dodson E . National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer. Ann Intern Med. 2012; 156(8):591-5. PMC: 4774889. DOI: 10.7326/0003-4819-156-8-201204170-00401. View

Jeldres C, Cullen J, Hurwitz L, Wolff E, Levie K, Odem-Davis K . Prospective quality-of-life outcomes for low-risk prostate cancer: Active surveillance versus radical prostatectomy. Cancer. 2015; 121(14):2465-73. PMC: 4490040. DOI: 10.1002/cncr.29370. View

Tosoian J, Loeb S, Epstein J, Turkbey B, Choyke P, Schaeffer E . Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools. Am Soc Clin Oncol Educ Book. 2016; 35:e235-45. PMC: 4917301. DOI: 10.1200/EDBK_159244. View

Bangma C, Bul M, van der Kwast T, Pickles T, Korfage I, Hoeks C . Active surveillance for low-risk prostate cancer. Crit Rev Oncol Hematol. 2012; 85(3):295-302. DOI: 10.1016/j.critrevonc.2012.07.005. View

de Cerqueira M, Laranja W, Sanches B, Monti C, Reis L . Burden of focal cryoablation versus brachytherapy versus active surveillance in the treatment of very low-risk prostate cancer: a preliminary head-to-head comprehensive assessment. Eur J Cancer Care (Engl). 2015; 24(6):929-37. DOI: 10.1111/ecc.12307. View

Saegrov S . Health, quality of life and cancer. Int Nurs Rev. 2005; 52(3):233-40. DOI: 10.1111/j.1466-7657.2005.00416.x. View

van den Bergh R, Essink-Bot M, Roobol M, Wolters T, Schroder F, Bangma C . Anxiety and distress during active surveillance for early prostate cancer. Cancer. 2009; 115(17):3868-78. DOI: 10.1002/cncr.24446. View

10.

Anderson J, Burney S, Brooker J, Ricciardelli L, Fletcher J, Satasivam P . Anxiety in the management of localised prostate cancer by active surveillance. BJU Int. 2014; 114 Suppl 1:55-61. DOI: 10.1111/bju.12765. View

11.

Tosoian J, Carter H, Lepor A, Loeb S . Active surveillance for prostate cancer: current evidence and contemporary state of practice. Nat Rev Urol. 2016; 13(4):205-15. PMC: 4940050. DOI: 10.1038/nrurol.2016.45. View

12.

Carter G, Clover K, Britton B, Mitchell A, White M, McLeod N . Wellbeing during Active Surveillance for localised prostate cancer: a systematic review of psychological morbidity and quality of life. Cancer Treat Rev. 2014; 41(1):46-60. DOI: 10.1016/j.ctrv.2014.11.001. View

13.

Pham K, Cullen J, Hurwitz L, Wolff E, Levie K, Odem-Davis K . Prospective Quality of Life in Men Choosing Active Surveillance Compared to Those Biopsied but not Diagnosed with Prostate Cancer. J Urol. 2016; 196(2):392-8. DOI: 10.1016/j.juro.2016.02.2972. View

14.

Simpkin A, Tilling K, Martin R, Athene Lane J, Hamdy F, Holmberg L . Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate Cancer. Eur Urol. 2015; 67(6):993-1005. DOI: 10.1016/j.eururo.2015.01.004. View

15.

Bastian P, Carter B, Bjartell A, Seitz M, Stanislaus P, Montorsi F . Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol. 2009; 55(6):1321-30. DOI: 10.1016/j.eururo.2009.02.028. View

16.

Banerji J, Hurwitz L, Cullen J, Wolff E, Levie K, Rosner I . A prospective study of health-related quality-of-life outcomes for patients with low-risk prostate cancer managed by active surveillance or radiation therapy. Urol Oncol. 2017; 35(5):234-242. DOI: 10.1016/j.urolonc.2016.12.015. View

17.

Wilcox C, Gilbourd D, Louie-Johnsun M . Anxiety and health-related quality of life (HRQL) in patients undergoing active surveillance of prostate cancer in an Australian centre. BJU Int. 2014; 113 Suppl 2:64-8. DOI: 10.1111/bju.12557. View

18.

Sanda M, Dunn R, Michalski J, Sandler H, Northouse L, Hembroff L . Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008; 358(12):1250-61. DOI: 10.1056/NEJMoa074311. View

19.

Whiting P, Moore T, Jameson C, Davies P, Rowlands M, Burke M . Symptomatic and quality-of-life outcomes after treatment for clinically localised prostate cancer: a systematic review. BJU Int. 2016; 118(2):193-204. DOI: 10.1111/bju.13499. View

20.

Punnen S, Cowan J, Dunn L, Shumay D, Carroll P, Cooperberg M . A longitudinal study of anxiety, depression and distress as predictors of sexual and urinary quality of life in men with prostate cancer. BJU Int. 2013; 112(2):E67-75. DOI: 10.1111/bju.12209. View